Rvl Pharmaceuticals

Pharmaceuticals, 400 Crossing BLVD, Bridgewater, New Jersey, United States, 201-500 Employees

rvlpharma.com

  • twitter
  • LinkedIn

phone no Phone Number: 90********

Who is RVL PHARMACEUTICALS

RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ...

Read More

map
  • 400 Crossing BLVD, Bridgewater, New Jersey, United States Headquarters: 400 Crossing BLVD, Bridgewater, New Jersey, United States
  • 1986 Date Founded: 1986
  • 201-500 Employees: 201-500
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from RVL PHARMACEUTICALS

RVL Pharmaceuticals Org Chart and Mapping

Employees

Ashlee Triglia

Business Development Manager

Cathy Carroll

Business Development Manager

Tsean Driscoll

Eye Care Territory Manager

Rebecca Garry

Business Development Manager Aesthetics

Kristi Ornelas

Business Development Manager

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding RVL Pharmaceuticals

Answer: RVL Pharmaceuticals's headquarters are located at 400 Crossing BLVD, Bridgewater, New Jersey, United States

Answer: RVL Pharmaceuticals's phone number is 90********

Answer: RVL Pharmaceuticals's official website is https://rvlpharma.com

Answer: RVL Pharmaceuticals's SIC: 2834

Answer: RVL Pharmaceuticals's NAICS: 325412

Answer: RVL Pharmaceuticals has 201-500 employees

Answer: RVL Pharmaceuticals is in Pharmaceuticals

Answer: RVL Pharmaceuticals contact info: Phone number: 90******** Website: https://rvlpharma.com

Answer: RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access